Sustained good momentum, but with some caution
18/11/22 -"After another quarterly performance beat in Q3, Novo remains on track to sustain its exceptional operating momentum. Besides our medium-term estimates resetting marginally higher, the DCF and NAV ..."
Pages
71
Language
English
Published on
18/11/22
You may also be interested by these reports :
02/02/23
Q4 sales met expectations, with both Pharmaceuticals and Diagnostics witnessing healthy growth, excluding receding COVID-19 testing tailwinds. In ...
02/02/23
Appreciating aprocitentan – How the royalty deal might look like – TP raised to CHF 18.20 (from 15.90) / Add reiterated
02/02/23
Novartis’ Q4 sales fell short of street expectations, although profitability improvements were noteworthy. The strong performances in Oncology and ...
31/01/23
We have integrated the first set of the 2022 figures. The significantly higher EPS stems mainly from the cancellation of the anticipated CHF-900m ...